



















# HIV Prevention Product Overview

| Product  | Yearly Dosage   | Frequency  | Delivery Site & Volume  | ARV Drug Class   | Efficacy & Efficacy Date   | Regulatory  | Developer       | Generic  | LMIC Cost Per Person Per Yr   |
|--|---|--|---|--|--|---|-----------------|--|---|
| <b>Oral PrEP (TDF/FTC) (TDF/xTC) (F/TAF)</b><br>       |    | One pill <b>every day</b> for all populations, with possibility of event-driven dosing of 2-1-1 for people assigned male at birth (TDF/FTC only) | TDF/FTC: Oral tablet with 200mg FTC and 300mg TDF<br><br>F/TAF: Oral tablet with 200mg FTC and 25mg TAF | Nucleoside reverse transcriptase inhibitor (NRTI)      | <b>TDF/FTC - 2010: High efficacy</b> among all populations (±90% with 7 doses/week); highly adherent-dependent<br><br><b>F/TAF - 2011: High efficacy</b> among cisgender men & trans women (±90% with 7 doses/week); highly adherent-dependent; PURPOSE 1 trial evaluating use in cisgender women, with results expected in 2027 | ±100 approvals since 2012; recommended by WHO in 2015   | Gilead Sciences | 15+ suppliers all over the world   | ±\$40   |
| <b>Dapivirine Vaginal Ring (DVR)</b><br>               |    | One ring <b>every month</b>  | Vaginal ring with 25mg dapivirine   | Non-nucleoside reverse transcriptase inhibitor (NNRTI) | <b>2016: Moderate efficacy</b> among cisgender women (35% risk reduction in efficacy trials; 50%+ reduction with consistent use in Open Label Extension studies); highly adherent-dependent  | 11 approvals as of Nov 2024; recommended by WHO in 2021 | IPM/PopCouncil  | MOU with Kiara in South Africa; details to come on license and timelines | \$156   |
| <b>Long-Acting Injectable Cabotegravir (CAB)</b><br> | Day 1  Month 7 <br>Month 1  Month 9 <br>Month 3  Month 11 <br>Month 5  | First injection followed by a second 1 month later, then <b>every 2 months</b>   | One 3 ml intramuscular injection in gluteal muscle (buttocks)   | Integrase strand transfer inhibitor (ISTI)             | <b>2020: Very high efficacy</b> in all populations (89% higher effectiveness in cisgender women and 66% in men who have sex with men and transgender women, compared to oral PrEP)   | 26 approvals as of Jul 2025; recommended by WHO in 2022 | Viiv Healthcare | 3 licenses via MPP, with expected earliest market access in 2027         | ≈\$160 (price set in GBP; USD equivalent is subject to currency fluctuations) |
| <b>Long-Acting Injectable Lenacapavir (LEN)</b><br>  | Day 1  + <br>Day 2 <br>Month 6 <br>Month 12    | First injection and two oral tablets, followed by two more tablets on day 2, then injections <b>every 6 months</b>                               | Two 1.5 ml subcutaneous injections in abdomen and two tablets with 300mg lenacapavir                    | Capsid inhibitor                                       | <b>2024: Very high efficacy</b> in all populations (100% efficacy among cisgender women, 96% reduction compared to background HIV incidence among cisgender men and trans and non-binary people)   | 1 approval as of Jun 2025; recommended by WHO in 2025   | Gilead Sciences | 6 direct licenses, with expected earliest market access in 2027          | TBD   |